Novacyt S.A. (CDI)
NCYT · AIM · Health Care · mcap £29m · 40.4p
| Date | Type | Announcement | Day |
|---|---|---|---|
| 01 Oct 26 | Liquidity Agreement Monthly Update and TVR
Liquidity Agreement Monthly Update and Total Voting Rights |
−4.8% | |
| 30 Sep 26 | Results | 2026 Interim Results
H1 2026 revenue up 18% to £11.6m; EBITDA loss reduced to £3.9m; cash fell to £8.9m; SCD acquisition contributing. |
−2.1% |
| 08 Sep 26 | Launch of IVDR-Certified Yourgene® DPYD Assay
Novacyt launches IVDR-certified Yourgene Insight DPYD assay for pharmacogenomic testing across European markets. |
+2.4% | |
| 01 Sep 26 | Master Collaboration Agreement with Illumina
Novacyt enters five-year Master Collaboration Agreement with Illumina to explore joint product development opportunities. |
+5.9% | |
| 03 Aug 26 | Liquidity Agreement Update and Total Voting Rights
Liquidity Agreement Monthly Update and Total Voting Rights |
+0.4% | |
| 28 Jul 26 | Trading update | Half-year trading update
H1 2026 revenue rose 18% to £11.6m with organic growth of 9% excluding SCD acquisition. |
−2.4% |
| 01 Jul 26 | Liquidity Agreement Monthly Update and TVR
Liquidity Agreement Monthly Update and Total Voting Rights |
+2.3% | |
| 10 Jun 26 | AGM Voting
Annual General Meeting scheduled for 30 June 2026 with voting procedures and shareholder participation details announced. |
−4.2% | |
| 01 Jun 26 | Liquidity Agreement Monthly Update and TVR
Liquidity Agreement Monthly Update and Total Voting Rights |
−3.8% | |
| 01 Jun 26 | Operational Update
Novacyt begins consultation on reducing headcount by up to 40% and expects £4.0m annual cash burn reduction. |
−3.8% | |
| 19 May 26 | Launch of Yourgene® Insight DPYD assay
Novacyt launches Yourgene Insight DPYD assay for cancer patient chemotherapy safety screening. |
+33.0% | |
| 07 May 26 | Board change | Directorate Change
Dr Joanne Mason steps down as Chief Scientific Officer and Board member with immediate effect. |
+40.1% |
| 05 May 26 | Liquidity Agreement Monthly Update and TVR
Liquidity Agreement Monthly Update and Total Voting Rights |
+5.5% | |
| 30 Apr 26 | Results | Full Year 2025 results
FY25 revenue £20.0m slightly above expectations; EBITDA loss improved to £7.8m; acquired Southern Cross Diagnostics post-year-end. |
−6.6% |
| 01 Apr 26 | Liquidity Agreement Monthly Update and TVR
Liquidity Agreement Monthly Update and Total Voting Rights |
−2.5% | |
| 20 Mar 26 | Fundraise | Result of Preferential Subscription Rights Issue
Novacyt raised €784,736 through preferential subscription rights issue of 1,961,840 new shares at €0.40. |
−1.7% |
| 02 Mar 26 | Liquidity Agreement Monthly Update and TVR
Liquidity Agreement Monthly Update and Total Voting Rights |
−2.7% | |
| 02 Mar 26 | Fundraise | Preferential Subscription Rights Issue
Rights issue to raise up to €784,736 at €0.40 per share, 1 new share for every 36 existing shares. |
−2.7% |
| 02 Mar 26 | Completion of Acquisition
Novacyt completes acquisition of Southern Cross Diagnostics Pty Ltd through subsidiary. |
−2.7% | |
| 23 Feb 26 | Acquisition of Southern Cross Diagnostics
Novacyt conditionally agrees to acquire Southern Cross Diagnostics for AUD$8.5m upfront plus up to AUD$16.5m in contingent consideration. |
+1.8% | |
| 02 Feb 26 | Liquidity Agreement Monthly Update and TVR
Liquidity Agreement Monthly Update and Total Voting Rights |
−1.5% | |
| 27 Jan 26 | NIPT Tender Award
Yourgene awarded NHS contract for NIPT testing with St George's University Hospitals for two years. |
−6.0% | |
| 21 Jan 26 | Trading update | Full year trading update
FY 2025 revenue of £20.0m met expectations; underlying growth 4%, instrumentation segment up 25%. |
+0.7% |
| 02 Jan 26 | Liquidity Agreement Monthly Update and TVR
Liquidity Agreement Monthly Update and Total Voting Rights |
+1.4% | |
| 01 Dec 25 | Liquidity Agreement Monthly Update and TVR
Liquidity Agreement Monthly Update and Total Voting Rights |
−0.7% | |
| 03 Nov 25 | Liquidity Agreement Monthly Update and TVR
Liquidity Agreement Monthly Update and Total Voting Rights |
+1.0% | |
| 22 Oct 25 | Strategy update & notice of investor presentation
Paris, France, and Manchester, UK - 22 October 2025 - Novacyt S.A. |
+8.5% |
Company filings. Not investment advice.